🚀 Pharmidex at Making Pharmaceuticals - Co-located with Distributing Pharmaceuticals UK 2025! 🚀
April 28, 2025
We are pleased to announce that Martin Barrett, our Head of Business Development, will be attending the Making & Distributing Pharmaceuticals UK event on 29–30 April 2025 at the Coventry Building Society Arena!
🔗 (https://lnkd.in/gd73pvE)
Martin would be delighted to meet with fellow attendees to discuss new collaboration opportunities and how we can work together to advance the development of innovative drug candidates.
If you are attending, don’t miss the chance to connect with us and explore how we can drive pharmaceutical progress forward together!
#Pharmidex #MakingPharma #DrugDevelopment #BusinessDevelopment #Innovation #Pharmaceuticals #Collaboration #Partnerships #MPD2025
We are delighted to announce and congratulate Ash Alavijeh on his appointment as Chief Operating Officer at Pharmidex . Ash has been an integral part of Pharmidex’s journey, bringing strong leadership, strategic vision and a deep commitment to advancing our capabilities in drug discovery and development. In his new role as COO, he will play a key part in driving operational excellence and supporting the continued growth of the company. This appointment reflects both Ash’s contributions to date and our confidence in his leadership as we continue to expand and evolve. Please join us in congratulating Ash on this well-deserved achievement.
Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN
